A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. - Sborov, Douglas W.; Canella, Alessandro; Hade, Erinn M.; Mo, Xiaokui; Khountham, Soun; Wang, Jiang; Ni, Wenjun; Poi, Ming; Coss, Christopher; Liu, Zhongfa; Phelps, Mitch A.; Mortazavi, Amir; et al. (Leukemia & Lymphoma, 2017)